Try our Advanced Search for more refined results
Life Sciences
-
February 24, 2026
6th Circ. Affirms Dismissal Of Sotera Toxic Gas Investor Suit
The Sixth Circuit on Tuesday affirmed a lower court's dismissal of an investor lawsuit accusing Sotera Health Co. of concealing the carcinogenic nature of a gas used at its sterilization plants, finding Sotera did not make any actionable false or misleading statements to investors.
-
February 24, 2026
Lindis Decries Erasing $50M Verdict Over Inequitable Conduct
A Delaware federal judge wrongly overruled Lindis Biotech's $50 million infringement verdict against Amgen by falsely concluding an inventor intended to deceive the patent office during prosecution, the German company has told the Federal Circuit.
-
February 24, 2026
High Court Won't Stay Dow Corning Breast Implant Fund Row
The U.S. Supreme Court on Tuesday denied a request to stay a lower court's order permanently wiping out the claims of more than 2,600 Koreans who said they were failed by how the settlement was structured, as they were given notice only in English regarding their claims.
-
February 24, 2026
Novo Nordisk Wants Expert Cut From Hospital Insulin Pen Suit
Novo Nordisk on Tuesday asked a Connecticut federal judge to remove an expert witness's report and related testimony from an insulin pen contamination lawsuit, hoping a hospital's entire case fails once the expert's opinions are blocked.
-
February 24, 2026
Mallinckrodt's Ch. 11 Blocks Antitrust Payouts, Judge Rules
A Connecticut federal judge has ruled that drugmaker Mallinckrodt PLC shrugged off monetary claims brought by states in a sprawling generic drug antitrust enforcement action when the company emerged from bankruptcy in 2022.
-
February 24, 2026
Philips Unit Escapes CPAP Machine Whistleblower Case
Philips Respironics, a unit of Koninklijke Philips NV, fended off a whistleblower suit alleging it provided kickbacks to CPAP suppliers that bought its products, with a Pennsylvania federal judge ruling that a former Philips manager failed to show that the company willfully engaged in illegal conduct.
-
February 24, 2026
Biotech Co. Moves To Dismiss LSD Trade Secret Suit
A biotechnology company accused of having lifted trade secrets regarding clinical trials of potential LSD treatments for psychiatric disorders asked a Delaware federal judge Monday to dismiss or narrow the suit, which it says was brought by a "disgruntled former vendor."
-
February 24, 2026
Suit Says Ex-Medco CFO Inflated Company's Value Before Sale
Medical supplier Medline Industries LP has sued the former chief financial officer of United Medco LLC in Florida state court, alleging the executive ran an overbilling scheme that led to an inflated valuation and purchase price for Medco and defrauded a customer of millions of dollars.
-
February 24, 2026
Headache-Focused Biotech Raises $130M In Series A Round
Headache disorder-focused biotech Slate Medicines Inc., advised by Cooley LLP, on Tuesday revealed that it wrapped a Series A funding round with $130 million in tow.
-
February 24, 2026
Life Sciences Group Of The Year: Gibson Dunn
Gibson Dunn & Crutcher LLP advised 89bio in a complex sale to Roche Holdings that could be worth up to $3.5 billion and won a precedent-setting victory that allowed Sun Pharma to launch an innovative alopecia treatment, earning a spot among the 2025 Law360 Life Sciences Groups of the Year.
-
February 24, 2026
AstraZeneca Drug Price Challenge Falls Short In Hawaii
A federal judge in Hawaii temporarily upheld the state's law that prevents drug manufacturers from blocking safety-net hospitals from contracting with an unlimited number of outside pharmacies to dispense discounted prescription drugs under the 340B Drug Discount Program.
-
February 24, 2026
Mintz Lands IP Pro From Wilson Sonsini In San Francisco
Mintz Levin Cohn Ferris Glovsky and Popeo PC. announced Tuesday that it has added a patent litigation attorney who was at Wilson Sonsini Goodrich & Rosati PC for more than two decades to bolster its intellectual property division.
-
February 24, 2026
8th Circ. Won't Revive Iowa Pathology Lab's Antitrust Claims
The Eighth Circuit has affirmed a lower court ruling that tossed a case accusing Iowa Pathology Associates of monopolizing pathology services in central Iowa, finding the rival never explained why doctors can't use labs that are located further away.
-
February 24, 2026
Judge Tosses Fitch Suit Against Ex-Client In Malpractice Row
An Illinois federal judge has dismissed a lawsuit brought by intellectual property law firm Fitch Even Tabin & Flannery LLP against the co-founder of a former patent client that accused it of malpractice, saying the firm was improperly seeking a declaration on state law claims without raising a federal question.
-
February 23, 2026
Bayer Sues J&J Over Alleged False Cancer Drug Claims
Johnson & Johnson is leaning on a flawed study to advertise its prostate cancer drug as having lower risk of death compared with Bayer's medication, alleged a New York federal lawsuit filed Monday by Bayer, which seeks to immediately halt J&J's advertising campaign and recover damages.
-
February 23, 2026
DC Circ. Talks Sharks, Moats In Vertex HHS Kickback Appeal
Sharks and moats were top of mind Monday morning for one judge on the D.C. Circuit, as gene therapy drugmaker Vertex Pharmaceuticals attempted to convince the court that its fertility preservation program does not violate the Anti-Kickback Statute.
-
February 23, 2026
Zynex Faces Securities Suit Following Arrest Of Former Execs
After being arrested last month on charges of securities fraud and conspiracy, the former CEO and ex-chief compliance officer of bankrupt medical device maker Zynex have been hit with a securities class action that alleges they and others caused the company to engage in fraudulent billing practices that inflated its stock price and led to investor losses once the truth came to light.
-
February 23, 2026
Synthego Urges Justices To Reject AI Bait In CRISPR Case
Synthego Corp. has called for the U.S. Supreme Court to turn away Agilent Technologies Inc.'s appeal of its invalidated CRISPR patents, saying the patent owner is inappropriately leveraging artificial intelligence to make the case sound more pressing than it is.
-
February 23, 2026
CBP Clears Redesigned Tourniquet Imports After IP Ban
U.S. Customs and Border Protection has found that a modified version of a tourniquet made by a Chinese company isn't subject to an import ban issued by the U.S. International Trade Commission after finding that earlier imports infringed a patent.
-
February 23, 2026
Corcept Mischaracterized Drug Approval Odds, Investor Says
Pharmaceutical company Corcept Therapeutics Inc. faces a proposed investor class action alleging it overstated approval prospects for a Cushing's syndrome drug candidate, hurting investors when its trading prices halved after it disclosed the U.S. Food and Drug Administration wouldn't accept the approval bid.
-
February 23, 2026
Philly-Area Fertility Clinic Settles Patient's Acid Burn Suit
A woman who sued a fertility clinic for allegedly mistakenly injecting her uterine cavity with acid, which she said caused her to suffer second-degree burns, has settled her lawsuit against the clinic for an undisclosed amount.
-
February 23, 2026
Justices Want Natera's Take On CareDx's False Ad Petition
The U.S. Supreme Court on Monday asked for Natera's position on a petition from rival CareDx asking the high court to review a Third Circuit decision that erased a $45 million jury award stemming from CareDx's false advertising claims.
-
February 23, 2026
Asthma Biotech Generate Biomedicines Eyes $400M IPO
Asthma-focused biotech firm Generate Biomedicines on Monday filed plans with U.S. regulators to raise around $400 million in its initial public offering led by Goodwin Procter LLP and Latham & Watkins LLP.
-
February 23, 2026
Life Sciences Group Of The Year: Ropes & Gray
Ropes & Gray LLP guided Gilgamesh Pharmaceuticals in a potentially $1.2 billion deal with AbbVie and advised Novo Nordisk in eight licensing and mergers and acquisitions transactions for novel obesity and metabolic disease treatments, earning the firm a spot among the 2025 Law360 Life Sciences Group of the Year.
-
February 23, 2026
Hims & Hers Misleads With GLP-1 Claims In Ads, Court Told
A class of GLP-1 patients claim that telehealth company Hims & Hers falsely advertised its compounded injections as made with "the same active ingredient" as weight loss drugs Ozempic and Wegovy despite containing other key ingredients, according to a suit filed in Illinois federal court.
Expert Analysis
-
Series
Law School's Missed Lessons: Client Service
Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.
-
How Occasional Activists Have Reshaped Proxy Fights
The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.
-
What To Expect After FDA Warnings To GLP-1 Compounders
The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.
-
Where 4th And 9th Circ. Diverge On Trade Secret Timing
Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.
-
Series
Adapting To Private Practice: 3 Tips On Finding The Right Job
After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.
-
Series
Painting Makes Me A Better Lawyer
Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.
-
Courts Are Still Grappling With McDonnell, 9 Years Later
The Seventh and D.C. Circuits’ recent decisions in U.S. v. Weiss and U.S. v. Paitsel, respectively, demonstrate that courts are still struggling to apply the U.S. Supreme Court’s 2016 ruling in McDonnell v. U.S., which narrowed the scope of “official acts” in federal bribery cases, say attorneys at Quinn Emanuel.
-
AI Will Transform Patent Examination For The Better
The U.S. Patent and Trademark Office's increasing use of artificial intelligence tools will result in patents that are more thoroughly vetted, and patent applicants and practitioners will need to adapt their drafting strategies and address stronger and more sophisticated rejections, say attorneys at Troutman.
-
Hybrid Claims In Antitrust Disputes Spark Coverage Battles
Antitrust litigation increasingly includes claims for breach of warranty, product liability or state consumer protection violations, complicating insurers' reliance on exclusions as courts analyze whether these are antitrust claims in disguise, says Jameson Pasek at Caldwell Law.
-
Drug Ad Crackdown Demonstrates Admin's Aggressive Stance
Recent actions by the U.S. Food and Drug Administration and U.S. Department of Health and Human Services targeting pharmaceutical companies' allegedly deceptive advertising practices signal an active — potentially even punitive — intent to regulate direct-to-consumer advertising out of existence, say attorneys at King & Spalding.
-
Protecting Sensitive Court Filings After Recent Cyber Breach
In the wake of a recent cyberattack on federal courts' Case Management/Electronic Case Files system, civil litigants should consider seeking enhanced protections for sensitive materials filed under seal to mitigate the risk of unauthorized exposure, say attorneys at Redgrave.
-
Series
Judging Figure Skating Makes Me A Better Lawyer
Judging figure skating competitions helps me hone the focus, decisiveness and ability to process complex real-time information I need in court, but more importantly, it makes me reengage with a community and my identity outside of law, which, paradoxically, always brings me back to work feeling restored, says Megan Raymond at Groombridge Wu.
-
Trending At The PTAB: Petitioners' Settled Expectations
Recent Patent Trial and Appeal Board decisions show that the U.S. Patent and Trademark Office's new "settled expectations" factor is no longer the exclusive domain of patent owners and can also provide petitioners with viable pathways to argue against discretionary denial, say attorneys at Finnegan.
-
9th Circ. Ruling May Help Pharma Cos. Avert Investor Claims
The Ninth Circuit's recent decision affirming the dismissal of a securities fraud class action alleging that Talphera deceived investors by marketing a drug with a misleading slogan should give plaintiffs pause before filing similar complaints where snappy slogans are accompanied by copious clarifying information, say attorneys at Simpson Thacher.
-
What Ethics Rules Say On Atty Discipline For Online Speech
Though law firms are free to discipline employees for their online commentary about Charlie Kirk or other social media activity, saying crude or insensitive things on the internet generally doesn’t subject attorneys to professional discipline under the Model Rules of Professional Conduct, says Stacie H. Rosenzweig at Halling & Cayo.